OCT 2 2 2003

K032590 P1/2

Section 2 - Summary of Safety and Effectiveness

(1) Company Information

MicroVention, Inc.
75 Columbia
Aliso Viejo, CA 92656
Telephone: (949) 768-1184
Fax: (949) 768-0464
www.microvention.com

(2) Contact Information

Vincent Cutarelli
Telephone: (949) 768-1184 ext. 105
Fax: (949) 768-0464
E-mail: vinc@microvention.com

(3) Device Name

Classification Name:	Device, Artificial Embolization
Trade/Proprietary Name:	Micro*Plex*™ Coil System (MCS) Hydro*Coil*® Embolic System (HES)
Common/Usual Name:	Embolization Coil

(4) Device Description

The Micro*Plex*™ Coil System (MCS) and Hydro*Coil*® Embolic System (HES) consist of an implantable coil attached to a fluid injection delivery system called a delivery pusher. The delivery pusher is a variable stiffness stainless steel tube with several outer layers of PET tubing. A luer hub at the proximal end of the pusher is used for system de-airing and coil detachment. The proximal end of the coil incorporates a coupler for attachment to the delivery pusher. PET tubing is heat-shrunk over the coupler/pusher junction in order to attach the coil to the delivery pusher. The coil is delivered to treatment site on the delivery pusher through standard neuro-interventional micro-catheters. An introducer sheath on the outside of the delivery pusher assists in the placement of the MCS and HES into the micro-catheter. A 1.0-cc syringe is used for system de-airing and a 0.25-cc syringe is used for coil detachment.

K032590 P2/2

(5) Indications for Use

The Micro*Plex*™ Coil System (MCS) and Hydro*Coil*® Embolic System (HES) are intended for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae.

The MCS and HES are also intended for vascular occlusion of blood vessels within the neurovascular system to permanently obstruct blood flow to an aneurysm or other vascular malformation and for arterial and venous embolizations in the peripheral vasculature.

(6) Name of Predicate or Legally Marketed Device

The MicroVention Micro*Plex*™ Coil System (MCS) and Hydro*Coil*® Embolic System (HES) with expanded indications for use are substantially equivalent to the Micro*Plex*™ Coil System that was determined to be substantially equivalent on July 29, 2002 (reference K020434) and the Micrus MicroCoil System that was determined to be substantially equivalent on August 1, 2003 (reference K031578).

(7) Technological Characteristics and Substantial Equivalence

The Micro*Plex*™ Coil System (MCS) and Hydro*Coil*® Embolic System (HES) with expanded indications for use are substantially equivalent in operating principle, method of application, indications for use, design, packaging and sterilization to the predicate devices.

(8) Performance Data Summary

Performance testing documented in K012145, K021914 and K020434, including tensile strength, coil detachment, simulated use and animal testing, has demonstrated that the Micro*Plex*™ Coil System (MCS) and Hydro*Coil*® Embolic System (HES) with expanded indications for use are equivalent in performance to the predicate devices.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

OCT 2 2 2003

Mr. Vincent Cutarelli
Vice President, Regulatory Affairs,
Quality Assurance and Clinical Affairs
MicroVention, Inc.
72 Argonaut
Aliso Viejo, California 92656

Re: K032590
Trade/Device Name: MicroPlex™ Coil System (MCS) and
HydroCoil® Embolic System (HES)
Regulation Number: 21 CFR 882.5950
Regulation Name: Artificial embolization device
Regulatory Class: III
Product Code: HCG
Dated: August 19, 2003
Received: August 22, 2003

Dear Mr. Cutarelli:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

for Mark N Melkerson

Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

K032590

Indications For Use

510(k) Number: _____

Device Name: Micro*Plex*™ Coil System (MCS) and Hydro*Coil*® Embolic System (HES)

Indications for Use: The Micro*Plex*™ Coil System (MCS) and Hydro*Coil*® Embolic System (HES) are intended for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae.

The MCS and HES are also intended for vascular occlusion of blood vessels within the neurovascular system to permanently obstruct blood flow to an aneurysm or other vascular malformation and for arterial and venous embolizations in the peripheral vasculature.

Concurrence of CDRH, Office of Device Evaluation (ODE):

for Mark N Melkerson

(Division Sign-Off)
Division of General, Restorative
and Neurological Devices

510(k) Number K032590

Prescription Use: _X_
(Per 21 CFR 801.109)